As reported in Annals of Internal Medicine, Dr. Rainer and colleagues compared the two drugs in a double-blind randomized trial of 416 patients with acute gout.
“When the study was first designed, steroids had very little place in national guidelines for the treatment of gout,” Dr. Rainer explained. “If they had any place then it was as a second-line treatment. It appeared that much more evidence was needed to convince expert reviewers and doctors in general. After the study started, there was some agreement from U.S. experts to include oral prednisolone as first line in national guidelines. But the same was not true elsewhere in the world.”
Both groups achieved similar clinically significant reductions in mean pain scores at rest and with activity during the two-week study.